2021 March 29

Sant Pau administers the first CAR-T of its own production for Hodgkin and non-Hodgkin lymphoma T in Europe

The first CAR-T immunotherapy drug produced entirely in Sant Pau (academic) and administered to the first patient is part of a pioneering clinical trial in Europe of CAR-T phase I / II immunotherapy for the autologous treatment of classical Hodgkin lymphoma and relapsed / refractory CD30 + non-Hodgkin T CD30 + lymphoma, funded by the Carlos III Health Institute and the Josep Carreras Leukaemia Foundation.